Xpediant Digital continued its yearslong collaboration with a large North American biomedical organization to help create their IVAs (Interactive Visual Aids) with Adobe Experience Manager (AEM) for one of their flagship products serving an immunology disease state.

Streamlining content authoring and go-to-market efforts with digital tools

As one of the largest pharmaceutical companies in the world, the company was looking for a modernized system that would allow them to create IVAs faster and more efficiently. Current operations were costly and largely non-reusable, rendering them slow to market. With existing inroads to adjacent teams and familiarity with the client’s business via XpGenerator®, Xpediant Digital was primed to partner with the client and built a proof of concept (POC) that matched as close as possible to their expected output.

The team worked in tandem with the client’s AEM implementation team to integrate XpConnect® and XpOmnichannel™, and built a customized solution to match their existing features and authoring experience within the environment.

A new operating model was also provided across Marketing and IT to support the new system post-implementation, and ensure teams felt empowered to uphold the new processes after the engagement.

This engagement also drove the development of a first-in-kind integration between Figma and AEM for the client. Through a custom plug-in, they can now create flows in Figma and have them translated directly to AEM without sacrificing design principles or brand integrity.

The pilot program with XpConnect® and XpOmnichannel™ resulted in the creation of more than 550 story points in about 2,800 hours, over a 50% time reduction and 40% cost saving from the client’s original IVA creation process. The success of the program, along with the added success of the custom plug-in for Figma and AEM, led to the almost immediate expansion of automating a similar design system across 5 more disease states for the client beginning in 2025.

Novo Nordisk

Bristol Myers Squibb

Goldman Sachs